Medicus selects 200 µg SkinJect patch as lead dose in final Phase 2 skin cancer study report
MDCX•Final Phase 2 SkinJect report points to 200 µg dose
- Medicus posted an abridged final Phase 2 SkinJect Clinical Study Report for nodular basal cell carcinoma on Sept. 10, 2026.
- Results were presented via public posting; the full dataset was submitted for future presentation at a major scientific congress.
- Final analysis supported the 200 µg D-MNA patch as the lead dose, with improving clearance over longer follow-up.
- Safety profile was described as favorable, with all 90 patients completing the study without discontinuations.
- Development focus shifts to FDA-authorized SKNJCT-005 in Gorlin syndrome, while seeking partners for a registrational nodular BCC program.
